Experimental leukemia drug trial halted early
NCT ID NCT02438761
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial tested a drug called PF-05212384 in people with certain acute myeloid leukemias or related blood cancers that came back or didn't respond to treatment. Only 10 people were enrolled before the study was stopped. The goal was to see if the drug could shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Toulouse
Toulouse, Midi-Pyrénées, 31059, France
-
Hôpital Cochin
Paris, Île-de-France Region, 75679, France
-
Hôpital Saint-Louis
Paris, Île-de-France Region, 75475, France
-
Institut Curie - Hôpital René Huguenin
Saint-Cloud, Île-de-France Region, 92210, France
-
Institut Paoli Calmette
Marseille, PACA, 13009, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-05212384 (PKI-587), a drug given intravenously
What this could lead to
If it works, this could point toward a new treatment option for certain hard-to-treat leukemias.
What could go wrong
This is a very early, small Phase 2 trial that was terminated early, so results are limited. The drug may not work or may cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.